

1 **CAR-T cells Targeting Thyroid-stimulating Hormone Receptor (TSHR)**
2 **Demonstrate Safety and Potent Preclinical Activity Against Differentiated**
3 **Thyroid Cancer**

4 Hanning Li^{1,2,3#}, Xiang Zhou^{4#}, Ge Wang^{1,2,3}, Dongyu Hua⁵, Shuyu Li^{1,2,3}, Tao Xu^{1,2,3,6},
5 Menglu Dong^{1,2,3}, Xiaoqing Cui^{1,2,3}, Xue Yang^{1,2,3}, Yonglin Wu^{1,2,3}, Miaomiao Cai⁴ Xinghua Liao⁴,
6 Tongcun Zhang⁴, Zhifang Yang^{1,2,3}, Yaying Du^{1,2,3,*} and Xingrui Li^{1,2,3,*}

7 **Affiliations**

- 8 1. Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College, Huazhong
9 University of Science and Technology (HUST), Wuhan, Hubei 430030, People's Republic of China
10 2. Laboratory of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College, Huazhong University
11 of Science and Technology (HUST), Wuhan, Hubei 430030, People's Republic of China
12 3. Laboratory of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science
13 and Technology (HUST), Wuhan, Hubei 430030, People's Republic of China
14 4. College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, Hubei,
15 430065, People's Republic of China
16 5. Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science
17 and Technology (HUST), Wuhan, Hubei 430030, People's Republic of China
18 6. Department of Obstetrics and Gynecology, Cancer Biology research center, Tongji Hospital, Tongji
19 Medical College, Huazhong University of Science and Technology (HUST), Wuhan, Hubei 430030,
20 People's Republic of China

21 # Co-first authors

22 * Correspondence

23 Address for correspondence :

24 Yaying Du, M.D., Ph.D.

25 Surgeon of Department of Thyroid and Breast Surgery, Tongji Hospital

26 Deputy Dean for Clinical Affairs, Laboratory of Thyroid and Breast Surgery

27 E-mail: yayingdu@hust.edu.cn

28 OR

29 Xing-rui Li, M.D., Ph. D.

30 Director and Professor of Department of Thyroid and Breast Surgery, Tongji Hospital

31 Dean for Clinical Affairs, Laboratory of Thyroid and Breast Surgery

32 E-mail: lixingrui@tjh.tjmu.edu.cn

33

34 Abstract

35 **Background:** Differentiated thyroid cancer (DTC) is usually very treatable and is often cured with surgery
36 and, if indicated, follow with radioactive iodine (RAI) and long-term thyroid-stimulating hormone (TSH)
37 suppression with levothyroxine. Unfortunately, locoregional relapse and distant metastases occur in up to
38 20% at ten years; those relapsed or distant metastatic thyroid cancer is relatively uncommon compare to
39 other cancers, cytotoxic chemotherapies provided low response rates, and two-thirds of cases became RAI
40 refractory (RAI-R). New therapy options for local-regional relapsed or distant metastases thyroid cancer are
41 desperately needed. Chimeric antigen receptor T cells (CAR-T) have been demonstrated remarkable efficacy
42 in hematological cancers but have not yet translated in treating solid tumors. The significant hurdles limiting
43 CAR-T therapy were due to a paucity of differentially expressed cell surface molecules on solid tumors that
44 can be safely targeted. Here, we present thyroid-stimulating hormone receptor (TSHR) as a putative target
45 for CAR-T therapy of DTC.

46 **Methods:** We undertook a large-scale screen on thyroid cancer tissues and multiple internal organs through
47 bioinformatical analysis and immunohistochemistry to date TSHR expression. Using three previously
48 described mAb, we generate three third-generation CAR-Ts. We tested anti-TSHR CAR-T in vitro activity
49 by T-cell function assay and killing assay. Then we tested pre-clinical therapeutical efficacy in a xenograft
50 mouse model of DTC and analyzed mice's physical conditions and histological abnormalities to evaluate
51 anti-TSHR CAR-T's safety.

52 **Results:** TSHR is highly and homogeneously expressed on 90.8%(138/152) of papillary thyroid cancer,
53 89.2% (33/37) of follicular thyroid cancer, 78.2% (18/23) of the cervical lymph node metastases, and 86.7%
54 of locally recurrent or metastasis lesions with RAI-R disease. We develop three novel anti-TSHR CAR-T
55 from mAb M22, K1-18, and K1-70, all three CAR-Ts mediate significant anti-tumor activity in vitro. Among
56 these, we demonstrate that K1-70 CAR-T can have therapeutical efficacy in vivo, and no apparent toxicity
57 has been observed.

58 **Conclusion:** TSHR is a latent target antigen of CAR-T therapy for DTC. Anti-TSHR CAR-T has strong
59 therapeutical efficacy in vivo while without prominent adverse events. Anti-TSHR CAR-T could represent
60 an exciting therapeutic option for patients with specific local-regional relapsed or distant metastases thyroid
61 cancer and should be tested in carefully designed clinical trials.

62 **Keywords:**

63 TSH Receptor, CAR-T, Differentiated Thyroid Cancer, adoptive transfer therapy, radioactive iodine
64 refractory DTC, tumor-specific antigens, targeted therapy

65 **Background**

66 The incidence of thyroid cancer has increased rapidly. 586,202 new cases of thyroid cancer occurred
67 globally in 2021¹, accounting for 3% of all tumors. Differentiated thyroid cancer (DTC), including papillary
68 thyroid cancer (PTC), follicular thyroid cancer (FTC), Hürthle cell carcinoma, and poorly differentiated
69 thyroid cancer (PDTC), arise from follicular cells and make up more than 95% of all of the thyroid cancers
70 ². DTC is biologically indolent compared to most solid tumors; thus, most patients have an excellent
71 prognosis. According to the clinical guideline, the patient should receive surgical interventions as the first-
72 line treatment, followed by long-term levothyroxine suppression of thyroid-stimulating hormone (TSH) and
73 ablation of the residual lesions by radioactive iodine (RAI)³. Unfortunately, locoregional relapse and distant
74 metastases occur in up to 20% and 10% at ten years, respectively⁴. Two-third of these cases will eventually
75 become refractory to RAI, with a 10-year overall survival of less than 10%⁵. Cytotoxic chemotherapies
76 provided low response rates (from 0% to 22% with the most frequently used agent, doxorubicin, at a dose
77 of 60 mg/m² every 3–4 weeks) and high toxicity⁶. Despite some small-molecule inhibitors being approved
78 for the treatment of RAI- refractory (RAI-R) locally advanced, or metastatic DTC, rapid disease progression
79 due to de novo or secondary drug resistance and toxic side effects occurred in a sizeable proportion of
80 patients, which severely limits their clinical application^{7 8}. Nevertheless, new therapy options for local-
81 regional relapsed or distant metastases of thyroid cancer are desperately needed.

82 Chimeric antigen receptor T cells (CAR-T) therapy redirects the cytotoxic activity of autologous,
83 patient-derived T cells independent of major histocompatibility complex (MHC) restrictions and without the
84 demand for antigen-triggered activation. CARs are synthetic receptors consisting of an extracellular antigen-
85 recognition moiety, usually antibody-derived, single-chain variable fragments (scFv) coupled to intracellular

86 activation, and costimulatory is endodomains from TCR CD3 ζ and CD28/4-1BB, respectively⁹. Engagement
87 of cognate antigen located on the tumor cells' surface by the CAR reprogrammed T cells initiates a cascade
88 of signaling activities leading to T cell activation and targeted killing of antigen-expressing cells¹⁰. Despite
89 remarkable evidence of clinical efficacy of CD19-targeted CAR-T cells for B-cell malignancies¹¹⁻¹³, CAR-
90 T therapy has exhibited limited effectiveness regarding the treatment of solid tumors¹⁴⁻¹⁶. The major
91 hindering facing the successful clinical promotion of CAR-T immunotherapy to solid tumors are suitable to
92 target antigens' paucity. Due to a lack of accessible tumor-specific antigens (TSAs), numerous tumor-
93 associated antigens (TAAs) currently under evaluation for CAR-T therapy are derived from overexpressed
94 endogenous cell-surface proteins, which present the risk of simultaneously inducing CAR recognition of the
95 same antigen expressed by healthy tissues and lead to “on-target, off-tumor” toxicities¹⁷.

96 The majority of DTC patients have experienced total or subtotal thyroidectomy before other treatment
97 regimens. While euthyroidism can be maintained by thyroxine replacement, the choice of target antigens
98 could be extended to thyroid tissue-specific proteins co-expressed in both the normal thyroid gland and DTC,
99 not just confined to TSAs or TAAs. One example is the thyroid-stimulating hormone receptor (TSHR), a
100 transmembrane glycoprotein receptor located on chromosome 14q31, belonging to a subfamily of G-protein-
101 coupled receptors¹⁸. TSHR is predominantly expressed in normal thyroid follicular epithelium, with some
102 expression on orbital and pretibial fibroblasts in some patients with Graves' disease¹⁹. In DTC, considerable
103 data have demonstrated the persistent expression of TSHR based on various detection methods, including
104 PCR²⁰, ligand binding²¹, and immunohistochemistry (IHC)²². TSHR is the endogenous receptor for TSH and
105 acts as the shared growth signaling receptor for benign thyrocytes and DTC²³. Indeed, growth-promoting
106 signals mediated through the TSH-TSHR transducing axis being therapeutically suppressed by
107 supraphysiological doses of levothyroxine in DTC management's clinical practice could also support the
108 continued expression and the importance for cell proliferation of TSHR in DTC cells. Notably, some
109 evidence has indicated that the TSHR expression is not restricted to primary tumors but is also frequently

110 observed in DTC metastases²¹⁻²⁴. Moreover, previous studies assessing thyroid differentiation markers of
111 resected DTC specimens suggest that TSHR remains stably expressed in the context of losing other markers,
112 such as NIS and thyroglobulin²⁵⁻²⁷. These data collectively point toward not only that TSHR is indispensable
113 for cell growth and survival of DTC but also serves as a promising target for CAR-T cell therapy.

114 In this study, we first evaluated the expression pattern of TSHR in various normal tissues and primary
115 and metastatic DTC specimens to validate that TSHR can serve as a suitable target for CAR-T therapy.
116 Subsequently, we assessed the biosafety and efficacy of TSHR CAR-T cell therapy both in vitro and in vivo,
117 and the results demonstrated pronounced eradication of DTC cell lines and xenograft tumors in a TSHR-
118 specific manner. Our proof-of-concept study provides a new therapeutic strategy for DTC patients with
119 relapsing and metastatic lesions postoperative, especially for those with RAI-refractory or inoperable tumors.

120

121 **Methods**

122 **Bioinformatics Analyses**

123 The tissue-specific expression of TSHR was queried from the Genotype-Tissue Expression portal
124 (GTEx, <http://www.gtexportal.org/>) and the Human Protein Atlas (HPA, <https://www.proteinatlas.org/>).
125 Moreover, the TSHR expression level among different subtypes of thyroid tumors, including benign nodule,
126 differentiated thyroid carcinoma, and anaplastic thyroid carcinoma, was assessed by combining data analysis
127 GSE27155 and GSE76039, which are deposited at GEO database (<http://www.ncbi.nlm.nih.gov/geo/>).

128 **Human subjects and tissue samples**

129 Para-tumor normal thyroid tissues (n=57), primary PTC specimens (total n=152, conventional n=97,
130 other subtypes including follicular variant n=16, tall cell variant n=20, Hobnail variant n=11, Clear cell
131 variant n=4, Columnar variant n=4), primary FTC specimens (n=37), cervical regional lymph node
132 metastasis (n=23), and RAI-R diseases (n=15) were collected from thyroid cancer patients who received

133 surgical interventions in Tongji Hospital, Tongji Medical College of Huazhong University of Science and
134 Technology (Wuhan, China). Pathohistological diagnoses were evaluated and determined by two expert
135 pathologists from the Pathology Department of Tongji Hospital. The diagnostic criterion of RAI-R diseases
136 was based on clinical consensus and practice guidelines of I¹³¹ therapy in DTC from the American Thyroid
137 Association (ATA) and was also referred to the previous literature. The criteria are briefly indicated below:
138 i) Loss of RAI uptake in the post 131I therapy whole-body scans after thyroidectomy; ii) Original iodine-
139 sensitive lesions gradually lost the capacity to uptake RAI during 131I treatment; iii) Metastases identified
140 by imaging examinations, like PET/CT, CT, and MRI, exhibited a significant difference in iodine-uptake
141 ability. We also collected multiple tissues like the retro-orbital adipose/ connective tissues (n=15), pretibial
142 connective tissues (n=3), and thymuses (n=6) from patients who underwent surgical resection with non-
143 thyroid associated diseases. In addition, a tissue microarray (TMA) slide containing 24 types of normal
144 organs/tissues from 7 healthy donors was purchased from Shanghai Outdo Biotech Co., Ltd
145 (HOrgN090PT02, Shanghai, China) (Table S1). All human sample work was performed under the guidelines
146 of Medical Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science
147 and Technology (Institution Review Board Approval: TJ-C20180110). Each patient involved in the study
148 was asked to sign a written informed consent form and the specimens were anonymized and handled
149 according to accepted ethical and legal standards.

150 **Histological and immunohistochemical analysis**

151 Murine and human tissues were perfused with 10% neutral-buffered formalin, followed by paraffin
152 embedding and slice in 4 μm sections for hematoxylin and eosin (HE) staining or immunohistochemistry
153 (IHC) analysis. HE staining was conducted by Servicebio (Wuhan, China) following the standard protocols.
154 For IHC, sections were routinely deparaffinized in xylene and hydrated with gradient alcohol. Following
155 heat-induced antigen retrieval and endogenous peroxidase blocking procedure, the slides were incubated
156 with 10% normal goat serum for 1 h to closing unspecific antigen-binding sites. The sections were then

157 probed with primary antibodies against TSHR (Cat. MCA1571, 1:2000, BIO-RAD), CD3 (Cat. ab16669,
158 1:150, Abcam), GFP (Cat. ab290, 1:2000, Abcam) at 4 °C overnight and incubated with the appropriate
159 secondary antibodies at room temperature for 40 min, followed by color development 3,3'-diaminobenzidine
160 (DAB) chromogen. Hematoxylin counterstain was applied for nuclei visualization. Histological and
161 immunohistochemical analysis

162 Murine and human tissues were perfused with 10% neutral-buffered formalin, followed by paraffin
163 embedding and slice in 4 µm sections for hematoxylin and eosin (HE) staining or immunohistochemistry
164 (IHC) analysis. HE staining was conducted by Servicebio (Wuhan, China) following the standard protocols.
165 For IHC, sections were routinely deparaffinized in xylene and hydrated with gradient alcohol. Following
166 heat-induced antigen retrieval and endogenous peroxidase blocking procedure, the slides were incubated
167 with 10% normal goat serum for 1 h to closing unspecific antigen-binding sites. The sections were then
168 probed with primary antibodies against TSHR, CD3, GFP at 4 °C overnight and incubated with the
169 appropriate secondary antibodies at room temperature for 40 min, followed by color development 3,3'-
170 diaminobenzidine (DAB) chromogen. Hematoxylin counterstain was applied for nuclei visualization.

171 **Immunofluorescence**

172 Cells were seeded on laminin-coated climbing slips in 24-well plates at a density of 1×10^5 cells/well
173 one day before the assay. Slides were fixed with 4% paraformaldehyde for 15 min and then blocked with
174 10% goat serum for 1 h at room temperature. Afterward, slides were probed with primary anti-TSHR (Cat.
175 MCA1571, 1:200, BIO-RAD) mouse mAb at 4°C overnight, followed by incubation with a CY3-conjugated
176 goat anti-rabbit IgG (H.L.) antibody (Cat. ab6969, 1:1000, Abcam) for 45 min at room temperature. The cell
177 nuclei were counterstained with DAPI (4',6-diamidino-2-phenylindole) for 5min. Fluorescence images were
178 acquired using a confocal microscope (Zeiss LSM 880 Confocal Microscope).

179 **Quantitative real-time PCR (qRT-PCR)**

180 The transcript level of TSHR was quantified by qRT-PCR using the CFX96 Multicolor Real-time PCR
181 detection system (Bio-Rad, USA). Total RNA of cell lines stably expressing TSHR or empty vectors was
182 extracted utilizing an RNA isolation kit (Tiangen, China). cDNA was then synthesized from 1 µg of RNA
183 by HiScript reverse transcription kit (Vazyme Biotech Co., Ltd, China). qRT-PCR was performed using IQ
184 SYBR Green Supermix (Bio-Rad, USA) with the gene-specific primers (Table S2). The GAPDH gene was
185 taken as an internal reference to normalize TSHR gene expression. Data were quantified using the $2^{-\Delta\Delta Ct}$
186 algorithm.

187 **Cell line and culture**

188 HEK-293T and K1 cell lines were purchased from the American Type Culture Collection (ATCC).
189 Nthy-ori-3.1 and FTC133 cell lines were obtained from the European Collection of Authenticated Cell
190 Cultures (ECACC). BCPAP, TPC-1, and KTC-1 cell lines were acquired from the Cell Bank of Type Culture
191 Collection of the Chinese Academy of Sciences (Shanghai, China). HEK-293T cells were maintained in
192 DMEM medium (Gibco) supplemented with 10 % fetal bovine serum (FBS; Gibco) and 2 mM l-glutamine
193 (Meilunbio, China) and 1 % Penicillin/Streptomycin (P.S.; Meilunbio, China), while all other cell lines were
194 cultivated in RPMI-1640 medium (Gibco) with 10 % FBS and 1 % P.S. Cells were grown in a humidified
195 incubator at 37 °C in the presence of 5% CO₂.

196 **TSHR CAR construction and lentivirus production**

197 The anti-TSHR scFv sequences were derived from mAb M22, K1-18, or K1-70 and generated via gene
198 splicing by multistep overlap-extension PCR technique (OE-PCR) with a linker (GGGS×3) connecting
199 their variable region of the heavy chain (V.H.) and light chain (V.L.) and a C-terminal StrepII tag sequence
200 that allowed for CAR detection. The above constructs were then inserted into the pLVX-EF1α-3rdCAR
201 lentiviral backbone plasmid comprising CD8α hinge, CD28 transmembrane region, CD28, and 4-1BB

202 intracellular domain and CD3 ζ signaling motif. The correctness of each integrated plasmid was verified by
203 Sanger sequencing.

204 For lentivirus production, 293T cells were co-transfected with the pLVX-EF1 α -CAR transfer plasmid,
205 the packaging plasmid psPAX2, and envelope plasmid pMD2.G (gifts from Didier Trono, Addgene plasmid
206 # 12260, and # 12259, respectively) at a ratio of 4:3:1 using polyethyleneimine (PEI; Polysciences)
207 transfection reagent. The supernatants containing the lentiviral particles were collected 48 h and 72 h post-
208 transfection, filtered (with 0.22 μ m filters), and concentrated by ultracentrifugation (25000g for 3 h). Viral
209 titers were determined by infecting 293T cells with the recombinant lentivirus carrying StrepII tag via flow
210 cytometry.

211 **Firefly luciferase (f-Luc) and TSHR over-expressed cell lines construction.**

212 The lentiviral plasmid containing the full length of the human TSHR cDNA sequence and a puromycin
213 resistance gene sequence (#GV492), and the lentiviral plasmid containing fLuc transgene and a neomycin
214 resistance gene (#GV238) were purchased from Genechem company (Shanghai, China). The preparation of
215 lentiviruses was carried out the same as described previously. BCPAP and K1 cells were infected by
216 recombinant lentiviruses and screened for stable expression of TSHR or fLuc in the presence of 5 μ g/ml
217 puromycin (Sigma) or 400 μ g/ml G418 (Sigma).

218 **Generation and expansion of TSHR-CAR- transduced T cells.**

219 Blood specimens were obtained from healthy donors by venipuncture, and peripheral blood
220 mononuclear cells (PBMC) were isolated using lymphocyte separation solution (LTS10771; TBDscience,
221 China). CD3⁺ T cells were negatively selected by magnetic bead sorting with a Human T Lymphocyte
222 Enrichment kit (557874, B.D. biosciences, USA), then activating used the human T-cell TransAct™
223 (Miltenyi, Germany). The culture media is TexMACS (Miltenyi) with 5 % human serum albumin (Gemini,
224 USA), 30 I.U./ml interleukin-2 (IL-2), 2 mM glutamine and 1 % P.S. T cells were infected with CAR

225 lentivirus (multiplicity of infection = 3) in the presence of 6 µg/ml polybrene (Sigma) 24 h post-activation.
226 After transduction, T cells were continued to expand in a complete medium containing 200 I.U./ml IL-2, and
227 a fresh medium was added to maintain a density of 5×10^5 - 1×10^6 cells/ml.

228 **Cytotoxicity Assays In Vitro**

229 The cytotoxicity of different CAR-T cells against tumor cells was tested using both the lactate
230 dehydrogenase (LDH) cytotoxicity assay and firefly luciferase (f-Luc) activity assay.

231 For LDH assay, tumor cells (BCPAP, BCPAP-TSHR, K1, and K1-TSHR) were cultured in 96-well
232 format at a density of 2×10^4 cells co-cultured with CAR-T or N.T. cells at various effector: target (E: T)
233 ratios for 4 h. The LDH release from tumor cells following co-culture was assessed using a colorimetric
234 CytoTox 96 non-radioactive assay kit (Promega, USA). Four control groups were included: group 1, culture
235 background group with the only medium; group 2, maximum LDH release control group in which target
236 cells were mixed with 20 µl lysis solution 45 min before supernatant harvest to induce maximal LDH release;
237 group 3, tumor cell spontaneous LDH release group containing only tumor cells; group 4, T cell spontaneous
238 LDH release group containing only CAR-T or N.T. cells. After incubation, 50 µl supernatant was aspirated
239 and used for the LDH release detection. The supernatant was incubated with a 50 µl substrate mix for 30
240 min before adding an equal volume of stop solution. Absorbance was then recorded at 490 nm using a multi-
241 functional microplate reader (Molecular Devices, CA, United States). After background correction, the lysis
242 efficiency was calculated as follows: lysis efficiency = [(experimental LDH release – spontaneous LDH
243 release) / (maximum LDH release – spontaneous LDH release)] × 100 %.

244 For f-Luc activity assay, target cells were first lentivirally transduced to express f-Luc transgene as
245 described above and seeded on 96 wells at a density of 1×10^4 cells per well and conjugated with CAR-T or
246 N.T. cells in up to 6 replicate wells at different E: T ratios for 24 h. A separate group with only tumor cells
247 was referred to as the control group. After incubation, the plates were centrifuged at 300g for 5 min, and the
248 supernatants were then discarded. Subsequently, 200 µL of RPMI-1640 medium containing 150 µg/mL D-

249 luciferin (Yeasen, Shanghai, China) was added into each well, and the plates were incubated for 5 min at
250 room temperature with protection from light before measurement. Counts were acquired by using the same
251 microplate reader in the LDH assay. The percentage of specific lysis was calculated using the following
252 equation: $(\text{control group release} - \text{test release}) / \text{control group release} \times 100\%$.

253 **Cytokine secretion assay**

254 Target cells were harvested and co-cultured with CAR-T, or N.T. cells at a ratio of 1:1 (1×10^5 cells for
255 each) in 96-well U-bottom plates RPMI-1640 containing 2 % horse serum (Gibco, USA) in the absence of
256 any cytokines. Culture supernatants were collected after 24 h of incubation by centrifugation at 1000g for
257 10 min and then stored at -80°C until further use. The level of secreted IL-2 and IFN- γ were quantified by
258 human ELISA kits (E-EL-H0099c and E-EL-H0108c, respectively; Elabscience Biotechnology Co, Ltd.,
259 China) in strict accordance with the manufacturer's instructions.

260 All samples were analyzed using a NovoCyte 3000VYB Flow Cytometer System (Agilent
261 Technologies, Inc., China), and data were analyzed and compensated using FlowJo software (TreeStar Inc.,
262 Ashland, OR, USA).

263 Commercially purchased antibodies include mouse anti-human CD3-BB515 (Cat. 564465, BD), CD4-
264 BV421 (Cat. 562424, BD), CD8-APC (Cat. 560662, BD), CD45RA-BV510 (Cat. 563031, BD) and CCR7-
265 PE (Cat. 560765, BD). The human TSHR expression on thyroid cell lines was assessed by staining with anti-
266 human TSHR monoclonal antibody (Cat. MCA1571, 1:200, BIO-RAD) followed by APC-conjugated anti-
267 mouse IgG secondary antibody (Cat. ab130782, Abcam). The transduction efficiency of CAR was assessed
268 through StrepII-tag-FITC staining (Cat. A01736, Genscript). T cells' phenotyping was determined by
269 staining for CD3-BB515, CD4-BV421, CD8-APC, CD45RA-BV510, and CCR7-PE. 7-aminoactinomycin
270 (7-AAD; eBioscience) was added before FACS data acquisition in all studies to discriminate live cells from
271 dead cells.

272 **In vivo assessment of TSHR CAR-T cell efficacy**

273 All animal procedures complied with local animal ethical and welfare standards and were conducted
274 on a protocol approved by the Animal Ethics Committee of Huazhong University of Science and Technology
275 (HUST). 8-10-week-old male and female NOD. Cg-Prkdcscid IL2rgtm1Wjl / SzJ (NSG) mice were
276 purchased from Jackson laboratory and were used for subcutaneous xenograft model construction. Mice
277 received a subcutaneous injection of TSHR and f-Luc overexpressing K1 cells (5×10^6) in 200 μ l PBS. After
278 7 d, 5×10^6 CAR-T cells or untransduced human T (N.T.) cells in 100 μ l PBS or an equal volume of PBS
279 alone were injected into the tumor-bearing mice by tail vein. For bioluminescence imaging (BLI), D-luciferin
280 substrate (15 mg/ml, 200 μ l/mouse) was injected intraperitoneally, and the mice were imaged on a BLI
281 imaging system (IVIS Spectrum, Xenogen, CA, USA) for longitudinal measurements of tumor burdens in
282 vivo. At the experimental endpoint (day 40), animals were injected with D-luciferin substrate 10 min before
283 euthanization, and the hearts, lungs, livers, spleens, stomachs, intestines, kidneys, and bladders were
284 harvested and imaged ex vivo similarly. Subsequently, these organs were routinely fixed and embedded. The
285 HE staining was conducted to assess the potential histological changes among different groups, and IHC was
286 performed to detect the infiltration of human T cells into these organs. In some cases, mice were forced to
287 be sacrificed prior to the experimental endpoint due to ethical considerations, such as the tumor invades the
288 skin and causes ulceration or mice that exhibited a moribund state.

289 Analyzing T cells in the peripheral blood of mice by flow cytometry, blood samples were collected
290 from the orbital venous plexus in the time of 3, 10, 17 d after CAR-T cells administration. Absolute CD3+
291 T cell counts in the peripheral blood of NSG mice were measured utilizing anti-human CD3-BB515 and
292 CountBright™ counting beads (No. C36950, Life Technologies/Thermo Fisher Scientific, USA) in strict
293 accordance with the manufacturer's instructions.

294 **Statistical analysis**

295 All statistical methods are described in figure legends. The P values and statistical significance were
296 estimated for all analyses. The unpaired, two-sided, Mann–Whitney test was used to compare two groups.
297 One-way ANOVA, two-way ANOVA, Dunnett's multiple comparisons test, Tukey's multiple comparisons
298 test was used to compare multiple groups. Survival curves were compared using the log-rank Mantel–Cox
299 test. Data between two groups were analyzed using a two-tailed unpaired t-test. Multiple t-test using the
300 Holm-Sidak method was used for multiple group comparison. Different levels of statistical significance were
301 accessed based on specific p values and type I error cutoffs (0.05, 0.01, 0.001, 0.0001). Data analysis was
302 performed using GraphPad Prism v.8. and RStudio.
303

304 **Results**

305 **TSHR is highly and homogeneously expressed in DTC meanwhile rarely expressed in most normal** 306 **tissues**

307 It is well known that TSHR is highly expressed in the thyroid gland. However, there is some studies
308 demonstrate that TSHR also plays an essential role during normal cell metabolism. Thus, we first assess the
309 TSHR gene expression level at all tissues from the Genotype-Tissue Expression Portal (Fig. 1A). No surprise,
310 the TSHR expression in the thyroid is hundreds of times higher than in other tissues. Then we access the
311 protein expression for TSHR at all tissues from The Human Protein Atlas (Fig. 1B). As indicated, TSHR is
312 highly expressed in the thyroid and medium expressed in testis.

313 Nevertheless, TSHR has been reported a loss during cancer dedifferentiated. We first sought to
314 determine the expression strength and pattern of TSHR within DTC tissues. TSHR expression among
315 different thyroid tumors was assessed by combining data analysis GSE27155 and GSE76039; TSHR
316 expression levels were comparable high expression among DTC, benign nodules, and normal thyroid tissues;
317 however, they significantly decreased in ATC (Fig. 1C). We subsequently examined the TSHR protein
318 expression by IHC on clinical specimens, including para-tumor normal thyroid tissues (n=57), primary PTC
319 specimens (n=152), primary FTC specimens (n=37), cervical regional lymph node metastasis lesions (n=23),
320 and RAI-R specimens (n=15). TSHR was 100% expression in the normal thyroid gland with moderate (2+)
321 to strong (3+) staining; in primary carcinomas, TSHR was detected in 90.8% (138/152) of PTCs, 89.2%
322 (33/37) of FTCs, and 78.2% (18/23) of the cervical lymph node metastases, where 56.6%, 43.2%, 17.4% are
323 highly expressed (3+ intensity) respectively (Fig 1D and 2A, Table 1, Fig. S1). Among different subtypes of
324 PTCs, CPTCs possessed the highest positivity for TSHR expression, followed by FV-PTCs; we also found
325 the presence of TSHR with considerable frequency in TCV-PTCs, CCV-PTCs, and HV-PTCs, which
326 represent the pathologic types with a higher degree of invasive properties and are associated with unfavorable
327 prognosis of patients (Fig 2B, Table 1). Additionally, we observed positive TSHR staining in 86.7% of

328 locally recurrent or metastasis lesions from patients who have been diagnosed with RAI-R diseases and
329 undergone multiple surgical interventions and Radioiodine treatments (Fig 2C and S1, Table 1). These
330 results demonstrate the generalization of the TSHR expression in DTCs, and the malignancy grade may not
331 influence its expression.

332 Considering that the future target audience has already undergone the thyroidectomy before CAR-T
333 therapy as described above, it is unnecessary to struggle because TSHR tends to be highly expressed in
334 thyroid glands.

335 To assess the safety of anti-TSHR CAR-T therapy, we next move on exploring the TSHR expression
336 level in extrathyroidal tissues. Since the presence of TSHR-specific immunoreactivity in the retro-orbital
337 and pretibial tissues of some patients with Graves' disease has been previously reported^{28 29}, we first
338 determined whether its expression was restricted to the individual's Graves hyperthyroidism related
339 complications but not the healthy donors. Indeed, we did not detect the TSHR expression in all 15 retro-
340 orbital adipose/ connective tissues and 3 pretibial subcutaneous tissues from individuals without
341 hyperthyroidism; however, we found faintly positive (1+) IHC staining of TSHR in 4/6 specimens of gastric
342 mucosa and 2/3 cases of bladder epithelium (Fig. 3A, Table 2 and Table S1). IHC results from the HPA
343 database show that the Leydig cells in testis exhibited moderate staining intensity of TSHR, but we could
344 not detect positive staining in the testis tissues (n=7) from our TMA (Fig 3B, Table 2 and Table S1). On the
345 other hand, no positive IHC signal was detected in the other kinds of normal tissues (Fig 3B). These results
346 adequately illustrate the safety of TSHR as a potential target of CAR-T treatment for DTC.

347 **Construction of TSHR expression cancer cell lines and anti-TSHR CAR-T**

348 In sharp contrast to the ubiquitous expression of TSHR in DTC clinical samples, TSHR expression
349 appears to be absent in most DTC-derived cell lines. As illustrated in Figure S2A, the TSHR expression level
350 of nearly all thyroid cancer cell lines lies below the mean mRNA baseline based on the CCLE database
351 except for the ML-1 cell line, which was derived from a dedifferentiated follicular thyroid tumor recurrence.

352 The intriguing result was also confirmed in one normal thyroid cell line (Nthy-ori-3.1) and five DTC cell
353 lines (K1, BCPAP, TPC-1, KTC-1, and FTC133) by flow cytometry (Fig S2B) and immunofluorescence
354 (Fig S2C and S2D). TSHR was undetectable in Nthy-ori-3.1, K1, BCPAP, TPC-1 and KTC-1 by both assays,
355 while very lightly staining of TSHR in FTC133 was found by IF, but no positive signals were captured by
356 flow cytometry. The absence of this protein in commonly used DTC cell lines could be attributed to gene
357 mutation and culture-specific selective pressures in vitro and has been well documented in the literature [22,
358 23]. In order to establish cell lines with reliable TSHR expression for CAR-T efficiency evaluation, we
359 delivered lentivirus containing either vector control (GFP-Luc) or full-length coding region of the TSHR
360 gene (TSHR-GFP-Luc) fused with GFP and F-Luc proteins into two DTC cell lines (K1 and BCPAP). The
361 newly constructed cell lines were designated K1-Luc, K1-TSHR-Luc, BCPAP-Luc, and BCPAP-TSHR-
362 Luc. The proper expression and membrane localization of TSHR in these cell lines were validated by PCR,
363 flow cytometry, and immunofluorescence (Fig. 4A-C).

364 **Anti-TSHR CAR-Ts have solid therapeutic efficacy in vitro and the three scFv M22, K1-18, and K1-**
365 **70 displaying different memory cell population and antigen-stimulated proliferation.**

366 We created third generation (CD28.41BB.CD3- ζ) TSHR specific CAR recombinant molecules derived
367 from the scFv of three TSHR antibodies, M22, K1-18, and K1-70, which we hereafter refer to as 22-CAR,
368 18-CAR, and 70-CAR, respectively (Fig. 4D). Lentiviral transduction of these CAR constructs into primary
369 human T cells from four healthy donors yielded ranges between 25% and 60% positive infection, with no
370 significant difference in infection efficiency among the three groups (Fig. 4E-F). We found no significant
371 differences in CD4 versus CD8 ratio among these groups, indicating defectiveness of the self-toxicity
372 mediating by CAR lentivirus integration (Fig. 4G).

373 T cells' cytolytic abilities expressing 22-CAR, 18-CAR, and 70-CAR transgene were assessed using
374 short-time and long-time co-culture models. In the short-time co-culture model, the cytotoxicity of target
375 cells was evaluated after 4 h co-incubation with either CAR-T or untransduced T (N.T.) cells by measuring

376 the release of LDH into the medium supernatant during cell death. All three CAR-T cells exhibited an
377 impressive cytolytic potential against TSHR-positive cells but trivial cytotoxicity on TSHR-negative cells.
378 The percentages of TSHR-positive dying cells increased in an effector cells dose-dependent manner,
379 achieving a nearly 100 % efficiency at 10:1 E: T ratio, supporting a rapid and robust antigen-specific killing
380 effect (Fig. 5A). In the long-time co-cultivating model with F-Luc bioluminescence, the lysis efficiency was
381 still pronounced when the incubation time was prolonged to 24 h, yielding closely 30-40% TSHR-positive
382 cell deaths even at 0.25:1 E: T ratio, highlighting the serial killing potency and persistence of CAR-redirection
383 T cells (Fig. 5B).

384 We next evaluated the cytokine production of CAR-T cells upon stimulation with cognate antigen. In
385 this regard, CAR-T or N.T. cells were co-incubated with target cells at a 1:1 E.T. ratio for 72 h. Supernatants
386 were then collected, IL-2 and IFN- γ cytokine levels were measured by ELISA. As anticipated, engagement
387 with TSHR+ tumor cells induced large quantities of IL-2 and IFN- γ secretion in comparable proportions of
388 all three types of TSHR-specific CAR-T cells, but not in N.T. cells (Fig 5C and 5D). Of note, slightly but
389 statistically significant more IL-2 and IFN- γ cytokine release were observed when TSHR- cells were co-
390 incubated with 22-CAR or 18-CAR T cells than with 70-CAR or N.T. cells. This phenomenon will be
391 discussed later in the text. Collectively, the results presented above support the specificity of TSHR CAR-T
392 cell recognition and killing of DTC cells with TSHR expression.

393 Spontaneous antigen-independent CAR activation, also characterized as tonic signaling, can induce T
394 cell exhaustion, leading to shortened T cell persistence and impairment of anti-tumor activity *in vivo*³⁰. This
395 constitutive signaling is generally caused by the high-level surface density and multimeric protein formation
396 propensity of CAR molecules but also affected by numerous other factors, such as the length of the hinge
397 domain and the kinetic of scFv moiety^{31 32}. We thus seek to explore whether these three CAR constructs can
398 drive tonic signaling and exhaustion. We first determined the cell doubling period (CDP) during CAR-T cell
399 expansion, which was deemed concise indicative of tonic signaling³³. As shown in Figure 5E, the CDP of T

400 cells expressing 22-CAR and 18-CAR (~54 and ~51-fold amplification on day 13, respectively) was
401 evidently prolonged compared with that of T cells expressing 70-CAR and the N.T. cells (~360 and ~450-
402 fold amplification, respectively). T cell volume is another critical indicator since CAR-T cells with high-
403 level tonic signaling usually fail to return to a resting state and sustain with larger cell sizes after activation
404 with anti-CD3/CD28 beads in the absence of antigen stimulation. The volume of all three CAR-T and N.T.
405 cells gradually enlarged and peaked on day 5~7, supporting a full T-cell activated status. The volume of 70-
406 CAR T cells recovered to approximately the resting level on day 13, while 22-CAR and 18-CAR T cells
407 remain relatively large in cell size, indicating more muscular tonic signaling existed in these two CAR-T
408 cells (Fig. 5F and 5G).

409 We next assessed the apoptosis and cytokine production of these three CAR-T cells in the absence of
410 cognate antigen. In analogy with the results above, markedly increased apoptotic cells and inflammatory
411 factors by days 10-12 were observed in T cells expressing 22-CAR and 18-CAR compared with 70-CAR
412 (Fig. 5H). Ultimately, we conducted a subtype analysis of CD8⁺ T cells by measuring the expression of
413 CD45RA and CCR7. CD8⁺ T cells were further classified as naive (CD45RA⁺CCR7⁺, TN), central memory
414 (CD45RA⁻CCR7⁺, TCM), effector memory (E.M.; CD45RA⁻CCR7⁻), or terminally differentiated
415 (CD45RA⁺CCR7⁻, TEMRA) phenotypes. As shown in Figure 5I, the 70-CAR transgene integration
416 resulted in higher preservation of the T.N. and TCM populations compared with 22-CAR and 18-CAR on
417 day 7. In contrast, the latter two contain proportionally much more E.M. and TEMRA subsets, heralding the
418 propensity towards a terminally differentiated phenotype and exhaustion. In summary, these data supported
419 that 70-CAR conveyed much more limited tonic signaling and was superior to 22-CAR and 18-CAR in cell
420 expansion, survival, and less differentiated phenotype preservation and was therefore selected for subsequent
421 in vivo experiments.

422 **Anti-TSHR CAR-T is safe and has solid therapeutic efficacy in vivo**

423 To further investigate the anti-tumor activity of TSHR-targeted T cells in vivo, we established a
424 subcutaneous xenograft tumor model in NOD-SCID IL2r^{gnull} (NSG) mice. K1 cell line constitutively
425 expressing TSHR and GFP/F-Luc tag was injected subcutaneously into the left axilla of 8-week-old NSG
426 mice (5×10^6 cells per mouse) for tumor quantitation and tracking. Following confirmation of implanting by
427 bioluminescence signal 7 days post-injection, mice have received a single intravenous dose of 5×10^6 70-
428 CAR T cells (with approximately 30-40% transduction efficacies) or an equal number of 5×10^6 N.T. cells
429 or treated with PBS (Fig. 6A). Tumor burden post-infusion was monitored every 3 days by bioluminescence
430 imaging (BLI) (Fig. 6B-D). An arrest of tumor growth emerged at day 16 in the CAR-T infusion group, and
431 the tumor volume shrank until the observation endpoint at day 40. Unsurprisingly, the tumor size in N.T.
432 and PBS groups was progressively increased with no sign of regression. Moreover, administration with 70-
433 CAR T cells resulted in a long-term survival benefit compared to N.T. cells and PBS groups (Fig. 6E).

434 Moreover, we determined T cells' persistence in the peripheral blood by flow cytometric analysis with
435 anti-CD3 staining. The human CD3⁺ lymphocytes were detectable after 3 days post-infusion in both 70-
436 CAR T and N.T. groups, with slightly higher numbers in the 70-CAR T group than in the N.T. group.
437 Encouragingly, a rapid increase of circulating CD3⁺ cells in the 70-CAR T group was observed, with the
438 average number per microliter of whole blood being 643 at day 20 and 1822 at day 34, and no more CD3⁺
439 cells were trackable in the N.T. group at the same time point, conforming to a specific and continuous
440 expansion characteristic of 70-CAR T cells in vivo (Fig. 6F). We collected the tumor from day 20 and day
441 40, comparing CD3 staining by IHC, as Fig. 6G showed the 70-CAR group has more tumor infiltration
442 CD3⁺ T cells than the N.T. group, and the infiltration is increasing according to the CAR-T infusion time.
443 We analyzed mice's physical conditions and histological abnormalities to evaluate the potential on-target/
444 off-tumor toxicities of 70-CAR T cells in vivo. No significant changes in the body weights were observed
445 among all the three groups (Fig. 6C).

446 Similarly, no differences in diet and water consumption or physiological behavior were found among
447 these groups. Furthermore, the main visceral organs from the 70-CAR T group and the N.T. group were
448 collected for HE staining and anti-human CD3 staining; the results revealed no apparent histological damage
449 or T lymphocyte infiltration was detected either in the 70-CAR T group or N.T. group (Fig. S3B). Luciferase
450 activity monitored at one month *ex vivo* after dissection of significant organs from the mice revealed that
451 treatment with 70-CAR T cells significantly postponed metastatic focus formation in the lungs compared to
452 N.T. cells and PBS groups (Fig 6H and S3A). These data collectively support the safety and the absence of
453 toxic effects of anti-TSHR CAR T cells in *in vivo* mouse models.

454

455 **Discussion**

456 As one of the most common endocrine malignancies, DTC has been consistently considered to have an
457 excellent long-term prognosis. However, 10%-20% of patients may experience tumor locally recurrence or
458 distant metastases, especially in those with a progressive disease that has lost iodine uptake capability³⁴⁻³⁶.
459 Recent years have witnessed an increasing number of small-molecule inhibitors targeting BRAF-V600E
460 mutation and vascular endothelial growth factor (VEGF) pathway. However, currently available chemicals
461 and drug-resistant toxic side effects will limit their clinical application in the short term. Thus, developing
462 novel therapeutics for these patients is emergency needed.

463 The success with CD19-specific CAR-T cells has revolutionized the treatment landscape of
464 hematologic malignancies, and increasingly attempts in the field of solid tumors with this technology have
465 been reported. However, very few studies on CAR-T immunotherapy of thyroid cancer have yet been
466 performed. Min and coworkers developed a CAR-T cell system targeting ICAM-1 to treat anaplastic thyroid
467 carcinoma (ATC), which belongs to a rare but highly lethal type and only accounts for 1-2 % of thyroid
468 cancer³⁷. Liu et al. reported Unfortunately, no CAR-T research has been focused on DTC, despite it making
469 up the vast majority (>90%) of all thyroid cancers. Here, we present pre-clinical results using novel CAR

470 targeting TSHR, a well-known thyroid-specific antigen but a new candidate for immunotherapy. Besides,
471 we present a giant screen to date that TSHR is an attractive target for the CAR-T therapy of DTC. This
472 protein is highly and homogenously expressed on different pathological subtypes of DTC and cervical lymph
473 node metastases as well as the RAI-R lesions and absent from nearly all normal tissues. Patients who may
474 be suffered from recurrence or metastases thyroid cancer already have the surgery to remove all thyroid
475 gland, and there is no need to concern about CAR-T attack the normal thyroid gland. Furthermore, in our
476 study, TSHR-redirectioned CAR T cells eradicate TSHR+ DTC cells in vitro and xenograft models and do not
477 induce noticeable toxicity in mice.

478 The ideal target for CAR-T immunotherapy needs to meet the antigen's high expression in tumor tissues
479 while low or no expression in healthy ones. Previous reports have described TSHR is expressed in some of
480 the extrathyroidal tissues, including the adipose tissue³⁸, liver³⁹, and kidney⁴⁰. However, these findings were
481 not in accord with the data of large-scale high throughput RNA sequencing, in where TSHR was utterly
482 absent in the healthy tissues except for thyroid glands. Thus, we measured the expression of TSHR in various
483 tissues from collected clinical samples and a TMA of healthy tissues by IHC, and the results suggested that
484 this protein was absent in the overwhelming majority of tissues other than bladder epithelium and gastric
485 mucosa, albeit with much lower staining intensities comparing to thyroid glands. Moreover, as the main self-
486 antigen, TSHR was reported to be highly expressed in the orbital and pretibial adipose/connective tissues of
487 Graves' ophthalmopathy. However, its expression is confined to only these patients but not to normal
488 counterparts, as confirmed by IHC, and these findings were consistent with previous reports^{28 29}. We tested
489 the TSHR CAR-T safety in a xenograft mouse model of DTC and did not found any apparent toxicity in the
490 majority of organs. This result indicates that the TSHR expression on several normal tissues is a relatively
491 low expression to trigger the toxicity of CAR-T therapy, but this hypothesis needs to be confirmed in larger
492 and carefully designed early-phase clinical trials.

493 Finding an appropriate CAR from a previously published antibody is a fast and easy way to develop a
494 new CAR-T. Toward a CAR-based T cell targeting strategy in DTC, we adopted three scFvs from humanized
495 monoclonal anti-TSHR antibodies, M22, K1-18, and K1-70, fused them into third-generation CAR
496 constructs comprising of the CD28 transmembrane and intracellular activation domains containing a CD28
497 and 4-1BB co-stimulatory molecules. M22 and K1-18 are considered to have agonist activity⁴¹, whereas K1-
498 70 is thought to have antagonist activity with TSHR⁴². All three antibodies were developed by the laboratory
499 of Bernard Rees Smith and have been attempted to diagnose and treat Graves' disease^{43 44}. Our engineered
500 CAR-T cells with these three scFv moieties exhibited efficient and specific in vitro killing ability and
501 increased IL2 and IFN- γ secretion when co-cultured with human K1-TSHR and BCPAP-TSHR cells.
502 However, we observed stronger constitutive tonic signaling in 22-CAR and 18-CAR than in 70-CAR,
503 indicated by lower proliferation capacity, larger cell volume, more inflammatory factors secretion in the
504 absence of ligand stimulation, and a higher proportion of terminally differentiated T cells in the former two
505 groups. CARs with tonic signaling have been associated with impaired anti-tumor activity in vivo⁴⁵. The
506 definite mechanism concerning the difference in tonic signaling activation mediated by these three CARs
507 remains unknown. This disparity might be ascribed to the differences in distributing the acidic and basic
508 patches among these antibodies. However, a further detailed study is undoubtedly required. Finding a fine-
509 tuning affinity of scFv in future work would be more conducive to avoiding CAR-induced off-target effects.

510 To assess the efficacy and safety of TSHR CAR-T cells in vivo, we established a subcutaneous
511 xenograft model using NSG mice and the K1-TSHR cell line. The 70-CAR T cells were selected for in vivo
512 injection because of the relatively limited tonic signaling compared with the other two CAR constructs
513 described above. Systemic i.v. administration of 70-CAR T cells induced the significant retraction of tumors,
514 prolonged survival of mice, and no prominent toxicity was observed across the different treatment groups.
515 However, despite an accentuated decrease in tumor volume, a complete remission of tumors has not occurred
516 in the 70-CAR T treatment group. This may be due to downregulation or loss of antigen of tumor cells and

517 the suppressive tumor microenvironment, which would hinder the recognition and killing of tumor cells by
518 CAR-T cells. Structural modification in CAR molecules by incorporating immune-promoting cytokines,
519 blocking the PD-1 receptor^{46 47}, or introducing the CAR molecules into TRAC locus by CRISPR/Cas9
520 genome editing technology could perhaps address this further^{48 49}.

521 In summary, we report on a CAR-T directed at TSHR shows strong efficacy against DTC while having
522 feasibility and safety in vitro and in vivo. This study is the first attempt to employ CAR-T cell
523 immunotherapy in DTC and the first report that applying TSHR as a potent target for CAR-T therapy. Our
524 anti-TSHR CAR-T immunotherapy may provide a new therapeutic option for patients with DTC, especially
525 those with recurrence/metastasis or RAI-R disease, and could also serve as a novel postoperative systemic
526 therapy DTC.

527

528 **Figure legends**

529

530 **Figure 1. TSHR is a latent target antigen of CAR-T therapy for differentiated thyroid**

531 **cancer.** (A) Gene expression for TSHR at all tissues from the Genotype-Tissue Expression Portal. (B)

532 Protein expression for TSHR at all tissues from The Human Protein Atlas. (C) TSHR expression among

533 different thyroid tumors, including B.N., DTC, and ATC, NT, PDTC, was assessed by combining data

534 analysis GSE27155 and GSE76039. (D) Summary statistic for the percentage difference of TSHR IHC

535 staining in variant thyroid cancer and normal thyroid gland. Para-tumor normal thyroid tissues (n=57),

536 primary PTC specimens (n=152), primary FTC specimens (n=37), cervical regional lymph node

537 metastasis lesions (n=23), and RAI-R diseases (n=15). (E) Schematic diagram outlining current

538 therapeutic targeting of TSHR in DTC. TSHR: thyroid-stimulating hormone receptor; B.N.: benign

539 nodule; DTC: differentiated thyroid cancer; ATC: anaplastic thyroid carcinoma, NT: normal thyroid

540 tissue; PDTC: poorly differentiated thyroid cancer; IHC: immunohistochemistry; FTC: follicular

541 thyroid cancer; RAI-R: radioactive iodine resistance.

542

543 **Figure 2. TSHR immunohistochemistry staining in the normal thyroid samples and**

544 **tumor samples displaying different staining intensity.** (A) Top panel is Full-slide and

545 representative sections of thyroid gland showing intensity 2+ (moderate) and intensity 3+ (strong) by

546 TSHR IHC-staining, lower panel are sections of PTC, FTC, and metastatic L.N. showing strong

547 intensity of TSHR IHC-staining (magnification×100). (B) Representative TSHR IHC-stained sections

548 of variant DTC subtype. (C) Representative TSHR IHC-stained sections of RAI-R local recurrence

549 lesion and metastatic lesion. TSHR: thyroid-stimulating hormone receptor; IHC: immunohistochemical;

550 PTC: papillary thyroid cancer; FTC: follicular thyroid cancer; L.N.: cervical lymph node; RAI-R:

551 radioactive iodine resistance.

552

553 **Figure 3. TSHR immunohistochemistry staining in multiple tissues from healthy donors**
554 **displaying weak positive or negative staining intensity.**

555 (A) Representative TSHR IHC-stained sections of retro-orbital adipose/ connective tissues (n=15) and pretibial subcutaneous tissues (n=3)
556 showing negative staining results, positive (1+) IHC staining of TSHR in 4/6 specimens of gastric
557 mucosa, and 2/3 cases of bladder epithelium (magnification×100). (B) Representative TSHR IHC-
558 stained sections of 24 kinds of normal tissues showing negative staining results. IHC:
559 immunohistochemical; TSHR: thyroid-stimulating hormone receptor.

560

561 **Figure 4. Construction of TSHR expression cancer cell lines and anti-TSHR CAR-T.** (A)

562 Quantification of TSHR mRNA level comparing cancer cell lines K1/BCPAP with TSHR expression
563 cell lines K1-TSHR/BCPAP-TSHR which were transduction with lentivirus. (B-C) Representative flow
564 cytometry analysis plots (B) and immunofluorescence staining section (C) of cancer cell lines
565 K1/BCPAP and derived TSHR expression cell lines. (D) Schematic of CAR-T construct design for anti-
566 TSHR. (E)Efficiency of lentivirus-mediated anti-TSHR CAR integrated on human primary CD3+ T
567 cells using FACS, M22, K1-18, and K1-70 are three scFv sequence publication before. One
568 representative sample's data are shown for four biological replicates each. (F)Quantification of data
569 from (E), at MOI = 5 after lentivirus transduction for 5 d (n = 4 independent infection replicates).
570 (G)Quantification of efficiency of lentivirus-mediated anti-TSHR CAR integrated on human primary
571 CD4+ T cells and human primary CD8+ T cells, at MOI = 5 after lentivirus transduction for 5 d (n = 4
572 independent infection replicates). Unpaired two-sided t-test was used to assess significance,
573 ***P < 0.001, ns mean no significant difference, for all comparisons. Data are shown as mean, ± s.e.m.,
574 plus individual data points on the graph.

575

576 **Figure 5. Anti-TSHR CAR-Ts have solid therapeutic efficacy in vitro and the three scFv**
577 **M22, K1-18, and K1-70 displaying different memory cell population and antigen-**
578 **stimulated proliferation.** (A-B) Comparing cytotoxicity of control T cells and anti-TSHR CAR-T
579 cells after co-culture with tumor cells which is with or without TSHR expression as indicated. LDH
580 releasing assay were performed at different E/T ratios as indicated after 4 hours of co-culture (A);
581 Bioluminescence assay were performed at different E/T ratios as indicated after 24 hours of co-culture
582 (B). (C-D) Quantification of IFN γ and IL2 production of control T cells and anti-TSHR CAR-T cells
583 after co-culture with tumor cells which is with or without TSHR expression as indicated. Cytokine
584 release was measured at 1:1 E-T ratio for 72 hours using ELISA (cell culture replicates, n = 3). (E-G)
585 Tonic signal activation is assessed by cell proliferation (B) and T cell volume (F) after anti-CD3/CD28
586 beads stimulation, measured time-points as indicated, proliferation were measured by automated cell
587 counters of CAR-T cells or control T cells. (G) Quantification of data from (F), (cell culture replicates,
588 n = 3). (H) (Left) Representative flow cytometry analysis plot of apoptosis. (Right) Quantification of
589 apoptotic cell percentages in anti- TSHR CAR-T cells (infection replicates, n = 3). The marker
590 expression levels were measured after lentivirus transduction for 10 days. (I) (Left) Representative flow
591 cytometry plots of CCR7⁺ and CD45RA⁺ cells on control T cells or anti- TSHR CAR-T cells. (Right)
592 The frequency of different memory T cells on control or anti- TSHR CAR-T cells refer to CCR7⁺ and
593 CD45RA⁺ marker expression status (infection replicates, n = 3). The marker expression levels were
594 measured after lentivirus transduction for 13 days. Anti-TSHR CAR-T including M22, K1-18, K1-70
595 as indicated in the figure as 22-CAR, 18-CAR and 70-CAR respectively, two-way ANOVA was used
596 to assess significance. Unpaired two-sided t-test was used to assess significance, *P < 0.05, **P < 0.01,
597 ***P < 0.001 for all comparisons. Data are shown as mean \pm s.e.m., plus individual data points on the
598 graph. E: T, effector: target; LDH: lactate dehydrogenase; ELISA: Enzyme immunosorbent assay.
599

600 **Figure 6. Anti-TSHR CAR-Ts have solid therapeutic efficacy in vivo.** (A) Schematics of in
601 vivo experimental design. To assess the anti-tumor ability of 70-CAR T cells in vivo, mice were injected
602 with 5×10^6 K1-TSHR-GFP/f-Luc cells at day 0, 5×10^6 Control T cells or 70-CAR T cells, or PBS
603 were infused at day 7. Mice were imaged every 3 days. Collected the peripheral blood at time-point as
604 indicated. After termination, multiple internal organs were collected. (B) Bioluminescence imaging of
605 K1-TSHR-GFP/f-Luc thyroid cancer-bearing NSG mice after treatment with control T cells, PBS or
606 70-CAR T cells. Cancer burden was measured as maximum photon per s per cm² per steradian (p per
607 s per cm² per sr), each group n = 5. (C) Quantification of body weight over time, comparing normal T
608 cells, PBS and 70-CAR T cells. (D) Quantification of whole-body bioluminescence signal over time,
609 comparing normal T cells, PBS and 70-CAR T cells. (E) Kaplan-Meier survival curve analysis for
610 survival of mice treated with normal T cells, PBS and 70-CAR T cells. (F) (Left) Representative flow
611 cytometry plots of human CD3⁺ T cells in peripheral blood at indicated days. (Right) quantification of
612 the data of left panels, comparing normal T cells and 70-CAR T cells, Mann Whitney test was used to
613 assess significance. (G) High -power histology sections stained by CD3 of tumor derived from K1-
614 TSHR-GFP/F-luc cells in NSG mice after different treatment conditions at day 20 and day 40,
615 (magnification×100). (H) (Left) Representative images of lung metastatic growth of GFP-expressing
616 K1-TSHR cells and the corresponding histology sections stained by GFP, comparing treated by normal
617 T cells and 70-CAR T cells. Two-way ANOVA was used to assess significance. Unpaired two-sided
618 t-test was used to assess significance, *P < 0.05, **P < 0.01, ***P < 0.001 for all comparisons. Data are
619 shown as mean ± s.e.m., plus individual data points on the graph.
620

621 **Supplementary Figure Legends**

622

623 **Figure S1. TSHR immunohistochemistry staining of negative (-), low positive (+),**
624 **intermediate positive (++) , and strong positive (+++) protein expressing in thyroid tumors.**

625 TSHR: thyroid-stimulating hormone receptor; PTC: papillary thyroid cancer; FTC: follicular thyroid
626 cancer; RAI-R: radioactive iodine resistance.

627

628 **Figure S2. TSHR expression in thyroid cancer cell lines.** (A)The mRNA expression for TSHR
629 at multiple cancer cell lines from the Cancer Cell Line Encyclopedia. (B) Representative flow cytometry
630 analysis of immortalized normal human primary thyroid follicular epithelial cells (Nthy-ori-3.1)and
631 thyroid cancer cell lines. (C-D) Representative immunofluorescence staining section of multiple cell
632 lines, cancer cell line FTC133 showed weak positive staining (C), other cell lines including Nthy-ori-
633 3.1, TPC-1, KTC-1, BCPAP, K1 both showed negative staining (D).

634

635 **Figure S3. In vivo safety assessment of anti-TSHR CAR-T therapy.** (A) Representative
636 images of multiple internal organs, no growth of f-Luc-expressing K1-TSHR cells were detected and
637 no visible organ damage were found. (B) Representative histology sections of internal organs by
638 hematoxylin and eosin (H&E) staining or CD3 immunohistochemistry staining, comparing PBS,
639 normal T cells and 70 CAR-T group.

640

641 **Author Contributions**

642 Conceptualization: YD, XL. Experiment lead: HL, XZ Analytic lead: HL, XZ, DH, GW Assistance:
643 SL, TX, MD, XC, XY, YW, MC, XL, TZ, ZY Manuscript prep: HL, XZ, YD, XL Supervision: YD,
644 XL Research funding: YD, XL

646 **Acknowledgments**

647 We thank all members in Thyroid and Breast surgery laboratory, as well as various colleagues in
648 Department of General surgery, Tongji Hospital, Tongji Medical college, Huazhong university of
649 Science and Technology.

650 YD is supported by National Natural Science Foundation of China (No.81802676). XL is
651 supported Wuhan Youth Cadre Project (2017zqnlxr01 and 2017zqnlxr02), Clinical Research Physician
652 Program of Tongji Medical College, HUST(5001540018).

654 **Declaration of interest**

655 The authors declare that there is no conflict of interest.

657 **References**

- 658 1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence
659 and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021 doi:
660 10.3322/caac.21660 [published Online First: 2021/02/05]
- 661 2. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. *Lancet (London, England)*
662 2016;388(10061):2783-95. doi: 10.1016/s0140-6736(16)30172-6 [published Online First: 2016/06/01]
- 663 3. Sawka AM, Gagliardi AR, Haymart MR, et al. A Survey of American Thyroid Association Members
664 Regarding the 2015 Adult Thyroid Nodule and Differentiated Thyroid Cancer Clinical Practice Guidelines.
665 *Thyroid : official journal of the American Thyroid Association* 2020;30(1):25-33. doi:
666 10.1089/thy.2019.0486 [published Online First: 2019/12/14]
- 667 4. Capdevila J, Galofré JC, Grande E, et al. Consensus on the management of advanced radioactive iodine-
668 refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid
669 Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI). *Clinical &*
670 *translational oncology : official publication of the Federation of Spanish Oncology Societies and of the*
671 *National Cancer Institute of Mexico* 2017;19(3):279-87. doi: 10.1007/s12094-016-1554-5 [published
672 Online First: 2016/10/06]

- 673 5. Schmidt A, Iglesias L, Klain M, et al. Radioactive iodine-refractory differentiated thyroid cancer: an
674 uncommon but challenging situation. *Archives of endocrinology and metabolism* 2017;61(1):81-89. doi:
675 10.1590/2359-3997000000245 [published Online First: 2017/02/23]
- 676 6. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer.
677 *N Engl J Med* 2008;359(1):31-42. doi: 10.1056/NEJMoa075853 [published Online First: 2008/07/04]
- 678 7. Brose MS, Cabanillas ME, Cohen EE, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic
679 or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre,
680 open-label, phase 2 trial. *The Lancet Oncology* 2016;17(9):1272-82. doi: 10.1016/s1470-
681 2045(16)30166-8 [published Online First: 2016/07/28]
- 682 8. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid
683 cancer. *The New England journal of medicine* 2015;372(7):621-30. doi: 10.1056/NEJMoa1406470
684 [published Online First: 2015/02/12]
- 685 9. Guedan S, Calderon H, Posey AD, Jr., et al. Engineering and Design of Chimeric Antigen Receptors.
686 *Molecular therapy Methods & clinical development* 2019;12:145-56. doi: 10.1016/j.omtm.2018.12.009
687 [published Online First: 2019/01/23]
- 688 10. June CH, Sadelain M. Chimeric Antigen Receptor Therapy. *The New England journal of medicine*
689 2018;379(1):64-73. doi: 10.1056/NEJMra1706169 [published Online First: 2018/07/05]
- 690 11. Park JH, Riviere I, Gonen M, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic
691 Leukemia. *N Engl J Med* 2018;378(5):449-59. doi: 10.1056/NEJMoa1709919 [published Online First:
692 2018/02/01]
- 693 12. Qin H, Dong Z, Wang X, et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell
694 malignancies. *Sci Transl Med* 2019;11(511) doi: 10.1126/scitranslmed.aaw9414 [published Online First:
695 2019/09/27]
- 696 13. Chen YH, Zhang X, Cheng YF, et al. Long-term follow-up of CD19 chimeric antigen receptor T-cell
697 therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell
698 transplantation. *Cytotherapy* 2020;22(12):755-61. doi: 10.1016/j.jcyt.2020.08.002 [published Online First:
699 2020/08/31]
- 700 14. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. *Nat Rev Clin Oncol* 2019;16(6):372-
701 85. doi: 10.1038/s41571-019-0184-6 [published Online First: 2019/03/07]
- 702 15. Esfahani K, Roudaia L, Buhlaiga N, et al. A review of cancer immunotherapy: from the past, to the
703 present, to the future. *Curr Oncol* 2020;27(Suppl 2):S87-S97. doi: 10.3747/co.27.5223 [published Online
704 First: 2020/05/06]
- 705 16. Ma L, Dichwalkar T, Chang JYH, et al. Enhanced CAR-T cell activity against solid tumors by vaccine
706 boosting through the chimeric receptor. *Science* 2019;365(6449):162-68. doi: 10.1126/science.aav8692
707 [published Online First: 2019/07/13]
- 708 17. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration

- 709 of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Molecular therapy : the*
710 *journal of the American Society of Gene Therapy* 2010;18(4):843-51. doi: 10.1038/mt.2010.24
711 [published Online First: 2010/02/25]
- 712 18. Davies T, Marians R, Latif R. The TSH receptor reveals itself. *The Journal of clinical investigation*
713 2002;110(2):161-4. doi: 10.1172/jci16234 [published Online First: 2002/07/18]
- 714 19. Agretti P, De Marco G, De Servi M, et al. Evidence for protein and mRNA TSHr expression in fibroblasts
715 from patients with thyroid-associated ophthalmopathy (TAO) after adipocytic differentiation. *European*
716 *journal of endocrinology* 2005;152(5):777-84. doi: 10.1530/eje.1.01900 [published Online First:
717 2005/05/10]
- 718 20. Wang ZF, Liu QJ, Liao SQ, et al. Expression and correlation of sodium/iodide symporter and thyroid
719 stimulating hormone receptor in human thyroid carcinoma. *Tumori* 2011;97(4):540-6. doi:
720 10.1700/950.10410 [published Online First: 2011/10/13]
- 721 21. Carayon P, Thomas-Morvan C, Castanas E, et al. Human thyroid cancer: membrane thyrotropin binding
722 and adenylate cyclase activity. *The Journal of clinical endocrinology and metabolism* 1980;51(4):915-
723 20. doi: 10.1210/jcem-51-4-915 [published Online First: 1980/10/01]
- 724 22. Liu TR, Su X, Qiu WS, et al. Thyroid-stimulating hormone receptor affects metastasis and prognosis in
725 papillary thyroid carcinoma. *European review for medical and pharmacological sciences*
726 2016;20(17):3582-91. [published Online First: 2016/09/22]
- 727 23. Franco AT, Malaguarnera R, Refetoff S, et al. Thyrotrophin receptor signaling dependence of Braf-
728 induced thyroid tumor initiation in mice. *Proceedings of the National Academy of Sciences of the United*
729 *States of America* 2011;108(4):1615-20. doi: 10.1073/pnas.1015557108 [published Online First:
730 2011/01/12]
- 731 24. So YK, Son YI, Baek CH, et al. Expression of sodium-iodide symporter and TSH receptor in subclinical
732 metastatic lymph nodes of papillary thyroid microcarcinoma. *Annals of surgical oncology*
733 2012;19(3):990-5. doi: 10.1245/s10434-011-2047-y [published Online First: 2011/09/01]
- 734 25. Filetti S, Bidart JM, Arturi F, et al. Sodium/iodide symporter: a key transport system in thyroid cancer
735 cell metabolism. *European journal of endocrinology* 1999;141(5):443-57. doi: 10.1530/eje.0.1410443
736 [published Online First: 1999/11/27]
- 737 26. Lazar V, Bidart JM, Caillou B, et al. Expression of the Na⁺/I⁻ symporter gene in human thyroid tumors:
738 a comparison study with other thyroid-specific genes. *The Journal of clinical endocrinology and*
739 *metabolism* 1999;84(9):3228-34. doi: 10.1210/jcem.84.9.5996 [published Online First: 1999/09/16]
- 740 27. Gérard AC, Daumerie C, Mestdagh C, et al. Correlation between the loss of thyroglobulin iodination
741 and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas.
742 *The Journal of clinical endocrinology and metabolism* 2003;88(10):4977-83. doi: 10.1210/jc.2003-
743 030586 [published Online First: 2003/10/15]
- 744 28. Daumerie C, Ludgate M, Costagliola S, et al. Evidence for thyrotropin receptor immunoreactivity in

- 745 pretibial connective tissue from patients with thyroid-associated dermopathy. *European journal of*
746 *endocrinology* 2002;146(1):35-8. doi: 10.1530/eje.0.1460035 [published Online First: 2001/12/26]
- 747 29. Bahn RS, Dutton CM, Natt N, et al. Thyrotropin receptor expression in Graves' orbital
748 adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. *The Journal of clinical*
749 *endocrinology and metabolism* 1998;83(3):998-1002. doi: 10.1210/jcem.83.3.4676 [published Online
750 First: 1998/03/20]
- 751 30. Ajina A, Maher J. Strategies to Address Chimeric Antigen Receptor Tonic Signaling. *Molecular cancer*
752 *therapeutics* 2018;17(9):1795-815. doi: 10.1158/1535-7163.mct-17-1097 [published Online First:
753 2018/09/06]
- 754 31. Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic
755 signaling of chimeric antigen receptors. *Nature medicine* 2015;21(6):581-90. doi: 10.1038/nm.3838
756 [published Online First: 2015/05/06]
- 757 32. Frigault MJ, Lee J, Basil MC, et al. Identification of chimeric antigen receptors that mediate constitutive
758 or inducible proliferation of T cells. *Cancer immunology research* 2015;3(4):356-67. doi: 10.1158/2326-
759 6066.cir-14-0186 [published Online First: 2015/01/21]
- 760 33. Calderon H, Mamonkin M, Guedan S. Analysis of CAR-Mediated Tonic Signaling. *Methods in molecular*
761 *biology (Clifton, NJ)* 2020;2086:223-36. doi: 10.1007/978-1-0716-0146-4_17 [published Online First:
762 2019/11/11]
- 763 34. Viola D, Valerio L, Molinaro E, et al. Treatment of advanced thyroid cancer with targeted therapies: ten
764 years of experience. *Endocr Relat Cancer* 2016;23(4):R185-205. doi: 10.1530/ERC-15-0555 [published
765 Online First: 2016/05/22]
- 766 35. Naoum GE, Morkos M, Kim B, et al. Novel targeted therapies and immunotherapy for advanced thyroid
767 cancers. *Mol Cancer* 2018;17(1):51. doi: 10.1186/s12943-018-0786-0 [published Online First:
768 2018/02/20]
- 769 36. Anderson RT, Linnehan JE, Tongbram V, et al. Clinical, safety, and economic evidence in radioactive
770 iodine-refractory differentiated thyroid cancer: a systematic literature review. *Thyroid* 2013;23(4):392-
771 407. doi: 10.1089/thy.2012.0520 [published Online First: 2013/01/09]
- 772 37. Min IM, Shevlin E, Vedvyas Y, et al. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human
773 Thyroid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer*
774 *Research* 2017;23(24):7569-83. doi: 10.1158/1078-0432.ccr-17-2008 [published Online First:
775 2017/10/14]
- 776 38. Gagnon A, Langille ML, Chaker S, et al. TSH signaling pathways that regulate MCP-1 in human
777 differentiated adipocytes. *Metabolism: clinical and experimental* 2014;63(6):812-21. doi:
778 10.1016/j.metabol.2014.02.015 [published Online First: 2014/03/26]
- 779 39. Zhang W, Tian LM, Han Y, et al. Presence of thyrotropin receptor in hepatocytes: not a case of
780 illegitimate transcription. *Journal of cellular and molecular medicine* 2009;13(11-12):4636-42. doi:

- 781 10.1111/j.1582-4934.2008.00670.x [published Online First: 2009/02/04]
- 782 40. Sellitti DF, Akamizu T, Doi SQ, et al. Renal expression of two 'thyroid-specific' genes: thyrotropin
783 receptor and thyroglobulin. *Experimental nephrology* 2000;8(4-5):235-43. doi: 10.1159/000020674
784 [published Online First: 2000/08/15]
- 785 41. Núñez Miguel R, Sanders J, Chirgadze DY, et al. Thyroid stimulating autoantibody M22 mimics TSH
786 binding to the TSH receptor leucine rich domain: a comparative structural study of protein-protein
787 interactions. *Journal of molecular endocrinology* 2009;42(5):381-95. doi: 10.1677/jme-08-0152
788 [published Online First: 2009/02/18]
- 789 42. Sanders P, Young S, Sanders J, et al. Crystal structure of the TSH receptor (TSHR) bound to a blocking-
790 type TSHR autoantibody. *Journal of molecular endocrinology* 2011;46(2):81-99. doi: 10.1530/jme-10-
791 0127 [published Online First: 2011/01/21]
- 792 43. Furmaniak J, Sanders J, Rees Smith B. Blocking type TSH receptor antibodies. *Auto- immunity highlights*
793 2013;4(1):11-26. doi: 10.1007/s13317-012-0028-1 [published Online First: 2013/04/01]
- 794 44. Sanders J, Miguel RN, Furmaniak J, et al. TSH receptor monoclonal antibodies with agonist, antagonist,
795 and inverse agonist activities. *Methods in enzymology* 2010;485:393-420. doi: 10.1016/b978-0-12-
796 381296-4.00022-1 [published Online First: 2010/11/06]
- 797 45. Watanabe N, Bajgain P, Sukumaran S, et al. Fine-tuning the CAR spacer improves T-cell potency.
798 *Oncoimmunology* 2016;5(12):e1253656. doi: 10.1080/2162402x.2016.1253656 [published Online First:
799 2017/02/10]
- 800 46. Burr ML, Sparbier CE, Chan YC, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-
801 tumour immunity. *Nature* 2017;549(7670):101-05. doi: 10.1038/nature23643 [published Online First:
802 2017/08/17]
- 803 47. Wang G, Chow RD, Zhu L, et al. CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a
804 Major Modulator of Immune Checkpoint Blockade. *Cancer Discov* 2020;10(12):1912-33. doi:
805 10.1158/2159-8290.CD-19-1448 [published Online First: 2020/09/06]
- 806 48. Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9
807 enhances tumour rejection. *Nature* 2017;543(7643):113-17. doi: 10.1038/nature21405 [published
808 Online First: 2017/02/23]
- 809 49. Dai X, Park JJ, Du Y, et al. One-step generation of modular CAR-T cells with AAV-Cpf1. *Nat Methods*
810 2019;16(3):247-54. doi: 10.1038/s41592-019-0329-7 [published Online First: 2019/02/26]
- 811

Table 1. Expression of TSHR protein in different subtypes of DTC tissues.

Pathological type	Total numbers	IHC				Positive rate (%)
		-	+	++	+++	
PTC	152	14	20	32	86	90.8
subtypes						
Conventional	97	6	10	18	63	93.8
Follicular variant	16	1	3	2	10	93.7
Tall cell variant	20	3	3	5	9	85
Hobnail variant	11	1	2	4	4	90.9
Clear cell variant	4	1	1	2	0	75
Columnar variant	4	2	1	1	0	50
FTC	37	4	6	11	16	89.2
Cervical metastatic lymph node	23	5	6	8	4	78.2
RAI-R	15	2	4	4	5	86.7

Table 2. Expression of TSHR protein in various types of normal tissues

Tissues	Total numbers	IHC				Positive rate (%)
		-	+	++	+++	
Thyroid	61	-	-	43	17	100
Tongue	3	3	-	-	-	0
Esophagus	4	4	-	-	-	0
Stomach	6	2	4	-	-	66.7
Duodenum	2	2	-	-	-	0
Jejunum	6	6	-	-	-	0
Ileum	3	3	-	-	-	0
Appendix	5	5	-	-	-	0
Colon	4	4	-	-	-	0
Rectum	2	2	-	-	-	0
Liver	2	2	-	-	-	0
Pancreas	2	2	-	-	-	0
Trachea	3	3	-	-	-	0
Lung	5	5	-	-	-	0
Myocardium	3	3	-	-	-	0
Artery	3	3	-	-	-	0
Skeletal muscle	7	7	-	-	-	0
Skin	3	3	-	-	-	0
Seminal vesicle	1	1	-	-	-	0
Prostate	3	3	-	-	-	0
Testis	7	7	-	-	-	0
Bladder	4	1	2	-	-	66.7
Medulla oblongata	1	1	-	-	-	0
Telencephalon	2	2	-	-	-	0
Cerebellum	2	2	-	-	-	0
Brainstem	1	1	-	-	-	0
Spleen	2	2	-	-	-	0
Thymus	6	6	-	-	-	0
retro-orbital adipose/ connective tissues	15	15	-	-	-	0
pretibial connective tissues	3	3	-	-	-	0

Table S1. Tissue types and numbers of the TMA (HOrgN090PT02).

Tissue type	Number
Thyroid	4
Tongue	3
Esophagus	4
Stomach	6
Duodenum	2
Jejunum	6
Ileum	3
Appendix	5
Colon	4
Rectum	2
Liver	2
Pancreas	2
Trachea	3
Lung	5
Myocardium	3
Artery	3
Skeletal muscle	7
Skin	3
Seminal vesicle	1
Prostate	3
Testis	7
Bladder	4
Medulla oblongata	1
Telencephalon	2
Cerebellum	2
Brainstem	1
Spleen	2

TMA, tissue microarray.

Table S2. Primer sequence.

Gene	Forward 5'-3'	Reverse 5'-3'
TSHR	GGAATGGGGTGTTCGTCTCC	GCGTTGAATATCCTTGCAGGT
GAPDH	GGAGCGAGATCCCTCCAAAAT	GGCTGTTGTCATACTTCTCATGG

Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure S1






Figure S2


A



B



C



D





Figure S3

A



B

